Blue Earth Therapeutics intends to build a pipeline of precision targeted therapeutic radiopharmaceuticals, initially focused on prostate cancer, and with plans to expand into additional disease areas in oncology. The company is leveraging its radiopharmaceutical development experience, as demonstrated by the rapid success of its sister company Blue Earth Diagnostics, acquired by Bracco Imaging in 2019, to advance its nuclear medicine portfolio and apply its expertise to the world of next generation therapeutic radiopharmaceuticals.
About Bracco Imaging
Ad Statistics
Times Displayed: 22177
Times Visited: 440 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Bracco Imaging S.p.A. ("Bracco Imaging"), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities. Headquartered in Milan, Italy, Bracco Imaging's purpose is to improve people's lives by shaping the future of prevention and precision diagnostic imaging. Bracco Imaging portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine. In 2019 Bracco Imaging also enriched its product portfolio by expanding the range of oncology nuclear imaging solutions in the urology segment and other specialties with the acquisition of Blue Earth Diagnostics. The company is active in molecular imaging with innovative agents for positron emission tomography (PET) in patients with suspected recurrent prostate cancer.
About Blue Earth Therapeutics
Blue Earth Therapeutics, an indirect subsidiary of Bracco Imaging, S.p.A., is a clinical stage company dedicated to advancing next generation targeted radiotherapeutics to treat patients who have cancer. With proven management expertise across the spectrum of radiopharmaceutical and oncology drug development, as well as biotechnology start-up experience, the company aims to innovate and improve upon current technologies and rapidly advance new targeted therapies for serious diseases. Blue Earth Therapeutics has an emerging pipeline, initially focused on prostate cancer, and with plans to expand into additional disease areas in oncology. Blue Earth Therapeutics is based in Oxford, UK.
SOURCE Bracco Imaging S.p.A.
Back to HCB News
